Cargando…

Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A (1)H-Magnetic Resonance Spectroscopy Study

BACKGROUND: Antiangiogenic treatment of glioblastomas with Bevacizumab lacks predictive markers. Myoinositol (MI) is an organic osmolyte, with intracellular concentration changes depending on the extracellular osmolality. Since Bevacizumab markedly reduces tumor edema and influences the tumor microe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steidl, Eike, Pilatus, Ulrich, Hattingen, Elke, Steinbach, Joachim P., Zanella, Friedhelm, Ronellenfitsch, Michael W., Bähr, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198997/ https://www.ncbi.nlm.nih.gov/pubmed/28033329 http://dx.doi.org/10.1371/journal.pone.0168113

Ejemplares similares

Phospholipid Metabolites in Recurrent Glioblastoma: In Vivo Markers Detect Different Tumor Phenotypes before and under Antiangiogenic Therapy
por: Hattingen, Elke, et al.
Publicado: (2013)

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
por: Burger, Michael C., et al.
Publicado: (2017)

Longitudinal study on MRI and neuropathological findings: Neither DSC-perfusion derived rCBV(max) nor vessel densities correlate between newly diagnosed and progressive glioblastoma
por: Steidl, Eike, et al.
Publicado: (2023)

Perioperative cerebral ischemia promote infiltrative recurrence in glioblastoma
por: Thiepold, Anna-Luisa, et al.
Publicado: (2015)

Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients
por: Zeiner, Pia S., et al.
Publicado: (2019)

Gliomatosis cerebri (GC) growth pattern: A single-center analysis of clinical, histological, and molecular characteristics of GC and non-GC glioblastoma
por: Divé, Iris, et al.
Publicado: (2023)

Myoinositol to Total Choline Ratio in Glioblastomas as a Potential Prognostic Factor in Preoperative Magnetic Resonance Spectroscopy
por: KUMON, Masanobu, et al.
Publicado: (2021)

Non-Invasive Measurement of Drug and 2-HG Signals Using (19)F and (1)H MR Spectroscopy in Brain Tumors Treated with the Mutant IDH1 Inhibitor BAY1436032
por: Wenger, Katharina J., et al.
Publicado: (2020)

ERGO: A pilot study of ketogenic diet in recurrent glioblastoma
por: RIEGER, JOHANNES, et al.
Publicado: (2014)

Adrenal Insufficiency in Patients with Corticosteroid-Refractory Cerebral Radiation Necrosis Treated with Bevacizumab
por: Voss, Martin, et al.
Publicado: (2019)

Proton 1H- and Phosphorus 31P-MR spectroscopy (MRS) in asymptomatic HIV-positive patients
por: Schuettfort, Gundolf, et al.
Publicado: (2014)

Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern
por: Burger, Michael C., et al.
Publicado: (2017)

Myoinositol in Autoimmune Thyroiditis
por: Paparo, Sabrina Rosaria, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization
por: Urban, Hans, et al.
Publicado: (2022)

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
por: Niyazi, Maximilian, et al.
Publicado: (2015)

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy
por: Steidl, Eike, et al.
Publicado: (2021)

Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Chamberlain, Marc C.
Publicado: (2011)

The Acute Superficial Siderosis Syndrome — Clinical Entity, Imaging Findings, and Histopathology
por: Friedauer, Lucie, et al.
Publicado: (2022)

Single-shot bevacizumab for cerebral radiation injury
por: Voss, Martin, et al.
Publicado: (2021)

EGFR and mTOR as therapeutic targets in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2019)

A Paravermal Trans-Cerebellar Approach to the Posterior Fossa Tumor Causes Hypertrophic Olivary Degeneration by Dentate Nucleus Injury
por: Schaller-Paule, Martin A., et al.
Publicado: (2021)

Myoinositol in the Prevention of Gestational Diabetes Mellitus: Is It Sensible?
por: Sobota-Grzeszyk, Angelika, et al.
Publicado: (2019)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
por: She, Lei, et al.
Publicado: (2022)

Myoinositol: The Bridge (PONTI) to Reach a Healthy Pregnancy
por: Cavalli, Pietro, et al.
Publicado: (2017)

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
por: Reardon, D A, et al.
Publicado: (2012)

Maintenance of Energy Homeostasis during Calorically Restricted Ketogenic Diet and Fasting-MR-Spectroscopic Insights from the ERGO2 Trial
por: Wenger, Katharina J., et al.
Publicado: (2020)

Value of quantitative magnetic resonance imaging T1-relaxometry in predicting contrast-enhancement in glioblastoma patients
por: Hattingen, Elke, et al.
Publicado: (2017)

Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma
por: Nagpal, Seema, et al.
Publicado: (2011)

Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma
por: Kumar, Gunjesh, et al.
Publicado: (2021)

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial
por: Reardon, David A., et al.
Publicado: (2020)

Effect of Myoinositol and Antioxidants on Sperm Quality in Men with Metabolic Syndrome
por: Montanino Oliva, Mario, et al.
Publicado: (2016)

Myoinositol Improves Embryo Development in PCOS Patients Undergoing ICSI
por: Wdowiak, Artur
Publicado: (2016)

Corrigendum to “Myoinositol: The Bridge (PONTI) to Reach a Healthy Pregnancy”
por: Cavalli, Pietro, et al.
Publicado: (2018)

Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma
por: Scholz, Alexander, et al.
Publicado: (2015)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy
por: Maurer, Gabriele D, et al.
Publicado: (2011)

Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
por: You, Weir-Chiang, et al.
Publicado: (2023)

Matching Quantitative MRI Parameters with Histological Features of Treatment-Naïve IDH Wild-Type Glioma
por: Maurer, Gabriele D., et al.
Publicado: (2021)

Bevacizumab for the Treatment of Glioblastoma
por: Gil-Gil, Miguel J., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_g1jbjcpba31pcjno48k41e6ijh